Real-World data on caplacizumab for aTTP: a game changer in treatment?
NCT ID NCT04985318
First seen May 05, 2026 · Last updated May 19, 2026 · Updated 2 times
Summary
This study reviews medical records of 350 adults with acquired thrombotic thrombocytopenic purpura (aTTP) who received caplacizumab. Researchers want to see how doctors decide to use the drug, how well it works outside of clinical trials, and what factors predict complications. The goal is to create better treatment guidelines that improve patient outcomes and lower costs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University Hospital of Cologne
Cologne, 50937, Germany
Conditions
Explore the condition pages connected to this study.